Press Release

August 4, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sirs, Sub: Press Release regarding listing of Company’s shares on National Stock Exchange of India Limited (‘NSE’). We are pleased to inform you that the existing 2,94,30,987 equity shares of the Company are listed and admitted to dealings on the NSE today i.e. August 4, 2026 under the symbol FERMENTA and ISIN INE225B01021. Please find enclosed herewith a Press Release issued by the Company in this regard. Kindly take the same on your records. Thanking you, Yours faithfully, For Fermenta Biotech Limited Varadvinayak Khambete Company Secretary & Head - Legal Membership No. A33861 Encl: As above Fermenta Biotech Lists on India’s National Stock Exchange NSE FERMENTA | BSE 506414 | Bloomberg FERMENTA:IN | Reuters FERM.BO • Equity shares formally listed and admitted to dealings on the NSE • Dual BSE and NSE listing expected to increase accessibility • “Enables participation of wider community ”: Prashant Nagre - Managing Director Mumbai, 4 August 2026: Fermenta Biotech Limited, one of the world's largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional ingredients, green chemistry, APIs and customized food premixes, today announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE). Effective 4 August 2026, the Company’s 2,94,30,987 equity shares, of face value ₹5 each, have been listed and admitted to dealings on the NSE under the symbol FERMENTA and ISIN INE225B01021. The Company’s equity shares will continue to remain listed on the BSE under Scrip Code 506414. The milestone was commemorated through a ceremonial bell-ringing event held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex. Present were representatives from NSE, Fermenta’s Board and senior leadership team, and other stakeholders. The listing marks a milestone in Fermenta’s 75-year journey. Founded in 1951 and listed on the BSE since 1977, the Company has grown from its pharmaceutical and biotechnology foundations into a globally recognised manufacturer serving customers in more than 60 countries, anchored by decades of technical expertise and backed by rigorous global compliance standards and certifications. Listed on the BSE since 1977, Fermenta’s NSE listing reflects the Company’s growth, expanding global customer base and widening investor interest. It provides access to shareholders and market participants across both major Indian stock exchanges, supporting broader participation, improved visibility and more efficient price discovery. Comment from Prashant Nagre, Managing Director “Fermenta’s listing on the NSE represents a significant milestone in a landmark year for the Company, as we commemorate 75 years of Fermenta and nearly five decades as a publicly listed enterprise, alongside important recognitions in food safety and workplace culture. It reflects a journey shaped by resilience and a path forward defined by innovation, scale and focus. We will continue to enhance our capabilities across nutrition, food fortification, green chemistry and specialised solutions. The NSE listing further strengthens our capital-market presence and reaffirms our commitment to transparency, responsible governance and consistent engagement with shareholders. We extend our sincere appreciation to our promoters, Board, shareholders, employees, customers, partners and all other stakeholders for their continued confidence in Fermenta.” About Fermenta Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta's comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provides research- based custom solutions in green chemistry, APIs & intermediates, and environmental solutions. Safe Harbour Statement Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, slump sale transaction potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward- looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward- looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law. Contact Varadvinayak Khambete | varadvinayak.khambete@fermentabiotech.com